2 Way 250V 16A Black Interlocking PCB Screw Terminal Blocks NOS Terminal Blocks


  1. Home
  2. 2 Way 250V 16A Black Interlocking PCB Screw Terminal Blocks NOS
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
2 Way 250V 16A Black Interlocking PCB Screw Terminal Blocks NOS
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Number of Ports: 2
Nominal Pitch Spacing: 5mm Compatible Mounting Type: PCB
Contact Material: Metal Modified Item: No
MPN:

Cant find it

Compatible Wire Gauge (AWG): AWG 14-22
Voltage Rating: 250 V Actual Pitch Spacing: 5mm
Current Rating: 16 A Custom Bundle: No
Non-Domestic Product: No Number of Pins: 2
Unit Type: Unit Standards/Compliance: RU & CSA
Body Material: Some kind of plastic Current Type: 250v
Brand:

PCB

Rated Voltage: 250V
Termination Type: Screw Colour: Black
published on tue nov 09 2021

2 Way 250V 16A Black Interlocking PCB Screw Terminal Blocks NOS Terminal Blocks

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

2 Way 250V 16A Black Interlocking PCB Screw Terminal Blocks NOS Terminal Blocks

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS